Comparison of forward- and back-projection in vivo EPID dosimetry for VMAT treatment of the prostate

IPEM topical report: guidance for the clinical implementation of online treatment monitoring solutions for IMRT/VMAT

This report provides guidance for the implementation of online treatment monitoring (OTM) solutions in radiotherapy (RT), with a focus on modulated treatments. Support is provided covering the implementation process, from identification of an OTM solution to local implementation strategy. Guidance has been developed by a RT special interest group (RTSIG) working party (WP) on behalf of the Institute of Physics and Engineering in Medicine (IPEM). Recommendations within the report are derived from the experience of the WP members (in consultation with manufacturers, vendors and user groups), existing guidance or legislation and a UK survey conducted in 2020 (Stevenset al2021). OTM is an inclusive term representing any system capable of providing a direct or inferred measurement of the delivered dose to a RT patient. Information on each type of OTM is provided but, commensurate with UK demand, guidance is largely influenced byin vivodosimetry methods utilising the electronic portal imager device (EPID). Sections are included on the choice of OTM solutions, acceptance and commissioning methods with recommendations on routine quality control, analytical methods and tolerance setting, clinical introduction and staffing/resource requirements. The guidance aims to give a practical solution to sensitivity and specificity testing. Functionality is provided for the user to introduce known errors into treatment plans for local testing. Receiver operating characteristic analysis is discussed as a tool to performance assess OTM systems. OTM solutions can help verify the correct delivery of radiotherapy treatment. Furthermore, modern systems are increasingly capable of providing clinical decision-making information which can impact the course of a patient's treatment. However, technical limitations persist. It is not within the scope of this guidance to critique each available solution, but the user is encouraged to carefully consider workflow and engage with manufacturers in resolving compatibility issues.

AAPM Task Group Report 307: Use of EPIDs for Patient-Specific IMRT and VMAT QA

PURPOSE

Electronic portal imaging devices (EPIDs) have been widely utilized for patient-specific quality assurance (PSQA) and their use for transit dosimetry applications is emerging. Yet there are no specific guidelines on the potential uses, limitations, and correct utilization of EPIDs for these purposes. The American Association of Physicists in Medicine (AAPM) Task Group 307 (TG-307) provides a comprehensive review of the physics, modeling, algorithms and clinical experience with EPID-based pre-treatment and transit dosimetry techniques. This review also includes the limitations and challenges in the clinical implementation of EPIDs, including recommendations for commissioning, calibration and validation, routine QA, tolerance levels for gamma analysis and risk-based analysis.

METHODS

Characteristics of the currently available EPID systems and EPID-based PSQA techniques are reviewed. The details of the physics, modeling, and algorithms for both pre-treatment and transit dosimetry methods are discussed, including clinical experience with different EPID dosimetry systems. Commissioning, calibration, and validation, tolerance levels and recommended tests, are reviewed, and analyzed. Risk-based analysis for EPID dosimetry is also addressed.

RESULTS

Clinical experience, commissioning methods and tolerances for EPID-based PSQA system are described for pre-treatment and transit dosimetry applications. The sensitivity, specificity, and clinical results for EPID dosimetry techniques are presented as well as examples of patient-related and machine-related error detection by these dosimetry solutions. Limitations and challenges in clinical implementation of EPIDs for dosimetric purposes are discussed and acceptance and rejection criteria are outlined. Potential causes of and evaluations of pre-treatment and transit dosimetry failures are discussed. Guidelines and recommendations developed in this report are based on the extensive published data on EPID QA along with the clinical experience of the TG-307 members.

CONCLUSION

TG-307 focused on the commercially available EPID-based dosimetric tools and provides guidance for medical physicists in the clinical implementation of EPID-based patient-specific pre-treatment and transit dosimetry QA solutions including intensity modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) treatments.

Error detection using EPID-based 3D in vivo dose verification for lung stereotactic body radiotherapy

PURPOSE

To investigate the error detectability limitations of an EPID-based 3D in vivo dosimetry verification system for lung stereotactic body radiation therapy (SBRT).

METHODS

Thirty errors were intentionally introduced, consisting of dynamic and constant machine errors, to simulate the possible errors that may occur during delivery. The dynamic errors included errors in the output, gantry angle and MLC positions related to gantry inertial and gravitational effects, while the constant errors included errors in the collimator angle, jaw positions, central leaf positions, setup shift and thickness to simulate patient weight loss. These error plans were delivered to a CIRS phantom using the SBRT technique for lung cancer. Following irradiation of these error plans, the dose distribution was reconstructed using iViewDose™ and compared with the no error plan.

RESULTS

All errors caused by the central leaf positions, dynamic MLC errors, Jaw inwards movements, setup shifts and patient anatomical changes were successfully detected. However, dynamic gantry angle and collimator angle errors were not detected in the lung case due to the rotation-symmetric target shape. The results showed that the γ_mean and γ_passrate indicators can detect 13 (81.3%) and 14 (87.5%) of the 16 errors respectively without including the gantry angle error, collimator angle error and output error.

CONCLUSIONS

In summary, iViewDose™ is an appropriate approach for detecting most types of clinical errors for lung SBRT. However, the phantom results also showed some detectability limitations of the system in terms of dynamic gantry angle and constant collimator angle errors.

A recurrent neural network for rapid detection of delivery errors during real-time portal dosimetry

Background and purpose

Real-time portal dosimetry compares measured images with predicted images to detect delivery errors as the radiotherapy treatment proceeds. This work aimed to investigate the performance of a recurrent neural network for processing image metrics so as to detect delivery errors as early as possible in the treatment.

Materials and methods

Volumetric modulated arc therapy (VMAT) plans of six prostate patients were used to generate sequences of predicted portal images. Errors were introduced into the treatment plans and the modified plans were delivered to a water-equivalent phantom. Four different metrics were used to detect errors. These metrics were applied to a threshold-based method to detect the errors as soon as possible during the delivery, and also to a recurrent neural network consisting of four layers. A leave-two-out approach was used to set thresholds and train the neural network then test the resulting systems.

Results

When using a combination of metrics in conjunction with optimal thresholds, the median segment index at which the errors were detected was 107 out of 180. When using the neural network, the median segment index for error detection was 66 out of 180, with no false positives. The neural network reduced the rate of false negative results from 0.36 to 0.24.

Conclusions

The recurrent neural network allowed the detection of errors around 30% earlier than when using conventional threshold techniques. By appropriate training of the network, false positive alerts could be prevented, thereby avoiding unnecessary disruption to the patient workflow.

Comparing treatment uncertainty for ultra- vs. standard-hypofractionated breast radiation therapy based on in-vivo dosimetry

Background and purpose

Postoperative ultrahypofractionated radiation therapy (UHFRT) in 5 fractions (fx) for breast cancer patients is as effective and safe as conventionally hypofractionated RT (HFRT) in 15 fx, liberating time for higher-level daily online Image-Guided Radiation Therapy (IGRT) corrections. In this retrospective study, treatment uncertainties occurring in patients treated with 5fx (5fx-group) were evaluated using electronic portal imaging device (EPID)-based in-vivo dosimetry (EIVD) and compared with the results from patients treated with conventionally HFRT (15fx-group) to validate the new technique and to evaluate if the shorter treatment schedule could have a positive effect on the treatment uncertainties.

Materials and methods

EPID-based integrated transit dose images were acquired for each treatment fraction in the 5fx-group (203 patients) and on the first 3 days of treatment and weekly thereafter in the 15fx-group (203 patients). A total of 1015 EIVD measurements in the 5fx-group and 1144 in the 15fx-group were acquired. Of the latter group, 755 had been treated with online IGRT correction (i.e., Online-IGRT 15fx-group).

Results

In the 15fx-group 12.0% of fractions failed (FFs) compared to 3.8% in the 5fx-group and 6.9% in the online-IGRT 15fx-group. Causes for FFs in the 15fx-group compared with the 5fx-group were patient positioning (7.4% vs. 2.2%), technical issues (3.1% vs. 1.2%) and breast swelling (1.4% vs. 0.5%). In the online-IGRT 15fx-group, 2.5% were attributed to patient positioning, 3.8% to technical issues and 0.5% to breast swelling.

Conclusions

EIVD demonstrated that UHFRT for breast cancer results in less FFs compared to standard HFRT. A large proportion of this decrease could be explained by using daily online IGRT.

A Large Area Pixelated Silicon Array Detector for Independent Transit In Vivo Dosimetry

A large area pixelated silicon array detector named “MP987” has been developed for in vivo dosimetry. The detector was developed to overcome the non-water equivalent response of EPID (Electronic Portal Imaging Device) dosimetry systems, due to the shortfalls of the extensive corrections required. The detector, readout system and software have all been custom designed to be operated independently from the linac with the array secured directly above the EPID, to be used in combination with the 6 MV imaging system. Dosimetry characterisation measurements of percentage depth dose (PDD), dose rate dependence, radiation damage, output factors (OF), profile measurements, linearity and uniformity were performed. Additionally, the first pre-clinical tests with this novel detector of a transit dosimetry characterization and a collapsed IMRT (intensity-modulated radiation therapy) study are presented. Both PDD and OF measurements had a percentage difference of less than 2.5% to the reference detector. A maximum change in sensitivity of 4.3 ± 0.3% was observed after 30 kGy of gamma accumulated dose. Transit dosimetry measurements through a homogeneous Solid Water phantom had a measured dose within error of the TPS calculations, for field sizes between 3 × 3 cm2 and 10 × 10 cm2. A four-fraction collapsed IMRT plan on a lung phantom had absolute dose pass fractions between the MP987 and TPS (treatment planning system) from 94.2% to 97.4%, with a 5%/5 mm criteria. The ability to accurately measure dose at a transit level, without the need for correction factors derived from extensive commissioning data collection procedures, makes the MP987 a viable alternative to the EPID for in vivo dosimetry. This MP987 is this first of its kind to be successfully developed specifically for a dual detector application.

Assessment of a commercial EPID dosimetry system to detect radiotherapy treatment errors

One method for detecting radiotherapy treatment errors is to capture the exit dose using an electronic portal imaging device. In comparison with a baseline integrated image, subsequent fractions can be compared and differences in images suggest a difference in the radiation treatment delivered. The aim of this work was to assess the sensitivity of a commercial software PerFRACTION in detecting such differences, arising from three possible sources: (i) changes in the radiation beam or EPID position; (ii) changes in the patient position; and (iii) changes in the patient anatomy. By systematically introducing errors, PerFRACTION was shown to be very sensitive to changes in the radiation beam. Variation in the beam output could be detected within 0.3%, field size within 0.4 mm, collimator rotation within 0.3° and MLC positioning could be verified to within 0.1 mm. EPID misalignment could be detected within 0.3 mm. PerFRACTION was able to detect the mispositioning of an anthropomorphic phantom by 3 mm with static beams, however there was a relative dependency between the patient geometry and the direction of the shift. VMAT beams were less sensitive to patient misalignments, with a shift of 10 mm only detectable once a strict criterion of 1% dose difference was applied. In another simulated scenario PerFRACTION was also able to detect a weight loss equivalent to a 5 mm change in patient separation in VMAT plans and 10 mm in conformal plans. This work showed that the PerFRACTION software could be relied upon to detect potential radiotherapy treatment errors, arising from a variety of sources.

Optimisation of a composite difference metric for prompt error detection in real-time portal dosimetry of simulated volumetric modulated arc therapy

OBJECTIVES

In real-time portal dosimetry, thresholds are set for several measures of difference between predicted and measured images, and signals larger than those thresholds signify an error. The aim of this work is to investigate the use of an additional composite difference metric (CDM) for earlier detection of errors.

METHODS

Portal images were predicted for the volumetric modulated arc therapy plans of six prostate patients. Errors in monitor units, aperture opening, aperture position and path length were deliberately introduced into all 180 segments of the treatment plans, and these plans were delivered to a water-equivalent phantom. Four different metrics, consisting of central axis signal, mean image value and two image difference measures, were used to identify errors, and a CDM was added, consisting of a weighted power sum of the individual metrics. To optimise the weights of the CDM and to evaluate the resulting timeliness of error detection, a leave-pair-out strategy was used. For each combination of four patients, the weights of the CDM were determined by an exhaustive search, and the result was evaluated on the remaining two patients.

RESULTS

The median segment index at which the errors were identified was 87 (range 40-130) when using all of the individual metrics separately. Using a CDM as well as multiple separate metrics reduced this to 73 (35-95). The median weighting factors of the four metrics constituting the composite were (0.15, 0.10, 0.15, 0.00). Due to selection of suitable threshold levels, there was only one false positive result in the six patients.

CONCLUSION

This study shows that, in conjunction with appropriate error thresholds, use of a CDM is able to identify increased image differences around 20% earlier than the separate measures.

ADVANCES IN KNOWLEDGE

This study shows the value of combining difference metrics to allow earlier detection of errors during real-time portal dosimetry for volumetric modulated arc therapy treatment.

Characterization of Gas Electron Multiplier-based detector for external beam radiation therapy dosimetry

PURPOSE

Electronic portal imaging devices (EPIDs) are commonly installed on modern linear accelerators (LINACs) and are convenient for imaging and, potentially, dosimetry. However, owing to their construction with metal and scintillating layers of high atomic number, they exhibit nonwater-equivalent response and oversensitivity to low-energy photons. Therefore, EPIDs are not ideal for dosimetry purposes. Additionally, nonlinearities due to the combined use of scintillators and photodiodes have been reported. Here, an EPID which employs a variable gain Gas Electron Multiplier (GEM) and direct detection of electrons is introduced. To investigate its dosimetric performance, measurements characterizing the novel EPID are performed and compared with measurements from ionization chambers and conventional EPIDs.

METHODS

Linearity, dose rate dependence, field size dependence, off-axis response, and transmission response were measured for all available energy settings (6, 10, 6 MV Flattening Filter Free (FFF) and 10 MVFFF) using three different detector gain settings. Additionally, an evaluation of the ghosting and image lag of the panel was completed. Reference ionization chamber measurements were performed for the off-axis and transmission response and existing data for conventional EPIDs and ionization chambers from equivalent measurements were used for comparison of the field size dependence. Elsewhere, values from the linac monitoring chambers were used.

RESULTS

In the range from 10 to 1000 Monitor Units (MU), the detector was linear within 1% for all combinations of gain settings and energies. The dose rate dependence was also within 1% for all energies and for two out of three gain settings. Regarding field size dependency, the ratio of ionization chamber and panel values was 0.94 and 0.98 for the conventional EPID and GEMini respectively, at 20 × 20 cm² and 10 MV. For 6 MV, 6 MVFFF, and 10MVFFF these ratios were 0.97, 0.98, and 0.99 for the GEMini, and 0.95, 0.97, and 0.97 for the conventional EPID. Similar performance between the GEMini and conventional EPID is observed for field sizes smaller than 10 × 10 cm² . The transmission response was within 5% for all energies for thicknesses up to 30 cm, compared to 10-20% for a conventional EPID. The off-axis response for shifts up to 16 cm was within 1% and 3% for 6 MV and 10 MV, with and without phantom. The rise and fall of the signal from the detector correspond well to monitor chamber measurements indicating little ghosting and image lag, regardless of gain setting.

CONCLUSION

The GEM EPID exhibits dose rate dependence and linearity within 1%, and negligible ghosting and image lag. In this regard, it performs particularly well using 50 and 250 V of gain, and either could be chosen. For higher sensitivity, 250 V is the recommended base gain setting, although other applications may warrant different gains. For most tests performed in this study, the GEM EPID demonstrates a more water-equivalent response than conventional EPIDs making GEMs a viable technology for dosimetry in radiation therapy.

Automatic dosimetric verification of online adapted plans on the Unity MR-Linac using 3D EPID dosimetry

BACKGROUND AND PURPOSE

The Unity MR-Linac is equipped with an EPID, the images from which contain information about the dose delivered to the patient. The purpose of this study was to introduce a framework for the automatic dosimetric verification of online adapted plans using 3D EPID dosimetry and to present the obtained dosimetric results.

MATERIALS AND METHODS

The framework was active during the delivery of 1207 online adapted plans corresponding to 127 clinical IMRT treatments (74 prostate, 19 rectum, 19 liver and 15 lymph node oligometastases). EPID reconstructed dose distributions in the patient geometry were calculated automatically and then compared to the dose distributions calculated online by the treatment planning system (TPS). The comparison was performed by γ-analysis (3% global/2mm/10% threshold) and by the difference in median dose to the high-dose volume (ΔHDV_D50). 85% for γ-pass rate and 5% for ΔHDV_D50 were used as tolerance limit values.

RESULTS

93% of the online plans were verified automatically by the framework. Missing EPID data was the reason for automation failure. 91% of the verified plans were within tolerance.

CONCLUSION

Automatic dosimetric verification of online adapted plans on the Unity MR-Linac is feasible using in vivo 3D EPID dosimetry. Almost all online adapted plans were approved automatically by the framework. This newly developed framework is a major step forward towards the clinical implementation of a permanent safety net for the entire online adaptive workflow.

Actual delivered dose calculation on intra-irradiation cone-beam computed tomography images: a phantom study

Cone-beam computed tomography (CBCT) images acquired during volumetric modulated arc therapy (VMAT; ii-CBCT) can be used to calculate actual delivered doses (ADDs). However, such ii-CBCT images are degraded by scattered megavoltage x-rays (MV-scatters). We aimed to evaluate the dose calculation accuracy of the MV-scatter uncorrected or corrected ii-CBCT images acquired during VMAT deliveries. For MV-scatter correction on concurrent kilovoltage projections (P _MVkV), projections consisting only of MV-scatters (P _MVS) were acquired under the same MV beam parameters and gantry angles and subtracted from P _MVkV (P _MVScorr). In addition, the projections by kilovoltage beams were acquired for reference (P _kV). The corresponding CBCT images were reconstructed using the Feldkamp-Davis-Kress algorithm (CBCT_MVkV, CBCT_MVScorr, and CBCT_kV as reference). A multi-energy phantom with rods of various relative electron densities (REDs) was used to generate a CBCT-number-to-RED conversion table. First, CBCT_kV was reconstructed. Then, the mean CBCT-numbers within each rod were extracted, and a reference table was generated. Concurrent kilovoltage imaging with various field sizes was also demonstrated, and CBCT_MVkV and CBCT_MVScorr were reconstructed. The extracted CBCT-numbers of each ii-CBCT image were converted into REDs using the reference table. Next, the absolute differences of RED between the ii-CBCT image and CBCT_kV were calculated. Ten VMAT plans using a 10 MV flattening-filter-free beam were used for concurrent imaging of an anthropomorphic torso phantom. Moreover, an iterative reconstruction algorithm (IRA) was used for CBCT_MVScorr. The plans were recalculated for the corresponding CBCT_MVkV, CBCT_MVScorr, CBCT_MVScorr+IRA, and CBCT_kV with the reference table. Finally, the doses were evaluated using 3D gamma analysis (1%/1 mm). The median difference ranges between CBCT_MVkV/CBCT_MVScorr and the reference values were -0.58 to -0.10/-0.03 to 0.00. The median gamma pass rates of the doses on CBCT_MVkV, CBCT_MVScorr, and CBCT_MVScorr+IRA to the rate on CBCT_kV were 70.4, 99.5, and 98.2%, respectively. CBCT_MVScorr were comparable with CBCT_kV for calculating the ADD from VMAT.

In vivo dosimetry for patients with prostate cancer to assess possible impact of bladder and rectum preparation

PURPOSE/OBJECTIVE

In all treatment sites of our radiotherapy network, in vivo dosimetry (PerFRACTION™) was fully implemented in February 2018. We hypothesized that additional help with bladder and rectum preparation by home nursing would improve patients' preparation and investigated if this could be assessed using in vivo dosimetry (IVD).

MATERIALS/METHODS

A retrospective study was conducted with a test group who received additional help with bladder and rectum preparation by home nurses and a control group who only received information on bladder and rectum preparation according to the standard protocol. Patients were treated with a 6 MV Volumetric Modulated Arc Therapy (VMAT) technique. Electronic portal imaging device (EPID)-based integrated transit dose images were acquired on the first 3 days of treatment and weekly thereafter or more if failed fractions (FF) occurred. Results were analyzed using a global gamma analysis with a threshold of 20%, tolerance of 5% (dose difference) and 5 mm (distance to agreement), and a passing level of 95%.

RESULTS

Data of 462 prostate patients was analyzed: 39 and 423 in a test and control group respectively with a comparable number of measurements (on average 8.0 (σ = 4.8) and 7.1 (σ = 4.5) respectively per treatment course). Of the FF, 39% and 31% were related to variations in bladder and rectum filling for the test and control group respectively. Subgroups were created based on the number of FF, no statistically significant differences were observed.

CONCLUSION

Two dimensional EPID-based IVD successfully detected deviations due to variations in bladder and rectum filling, however it could not confirm the hypothesis.

Using in vivo EPID images to detect and quantify patient anatomy changes with gradient dose segmented analysis

PURPOSE

To investigate the utility of gradient dose segmented analysis (GDSA) in combination with in vivo electronic portal imaging device (EPID) images to predict changes in the PTV mean dose for patient cases. Also, we use the GDSA to retrospectively analyze patients treated in our clinic to assess deviations for different treatment sites and use time-series data to observe any day-to-day changes.

METHODS

In vivo EPID transit images acquired on the Varian Halcyon were analyzed for simulated errors in a phantom, including gas bubbles, weight loss, patient shifts, and an arm erroneously in the field. GDSA threshold parameters were tuned to maximize the coefficient of determination (R² ) between GDSA metrics and the change in the PTV mean dose (D_mean ) as estimated in a treatment planning system (TPS). Similarly for a gamma analysis, the gamma criteria were adjusted to maximize R² between gamma pass rate and the change in the PTV D_mean from the TPS. The predictive accuracy of these models was tested on patient data measuring the mean and standard deviation of the difference in the predicted change in PTV D_mean and the change in PTV D_mean measured in the TPS. This analysis was extended retrospectively for every patient treated over a 23-month period (n = 852 patients) to assess the range of expected deviations that occurred during routine clinical operation, as well as to assess any differences between treatment sites. Grouping patients treated on the same day, a time-series analysis was performed to determine if GDSA metrics could add value in tracking machine behavior over time.

RESULTS

For the phantom data, analyzing the errors, except for shifts, and comparing the change in PTV D_mean and GDSA mean, a maximal R²  = 0.90 was found for a dose threshold of 5% and gradient threshold of 3 mm. For the gamma approach a linear fit between the gamma pass rate for change in the PTV D_mean was assessed for different criteria, using the same image data. A maximal, R²  = 0.84 was found for a gamma criteria of 3%/3 mm, 45% lower dose threshold. For patient data, the predictive accuracy of the change in the PTV D_mean using the GDSA approach and the gamma approach was 0.09 ± 0.98 % and - 0.65 ± 2.21%, respectively. Comparing the two approaches the accuracy did not significantly differ (P = 0.38), whereas the precision of the GDSA prediction is significantly less (P < 0.001). The dosimetric impact of shifts was not detectable with either the GDSA or gamma approach. Analysis of all patients treated over 23 months showed that over 95% of fractions treated deviated from the first fraction by 2% or less. Deviations> 2% occurred most frequently for the later fractions of head-and-neck and lung treatments. Additionally, averaging the GDSA mean metric over all patients on a given treatment day showed that changes in the machine output on the order of 1% could be identified.

CONCLUSIONS

GDSA of in vivo EPID images is a useful technique for monitoring patient changes during the course of treatment, particularly weight loss and tumor shrinkage. The GDSA mean provides a quantitative estimate of the change in the PTV D_mean , giving a simple, quantitative metric by which to flag patients with clinically meaningful deviations in treatment. Averaging the GDSA metric over all patients treated on a given day and tracking daily variations can also provide a flag for any systematic deviations in treatment due to machine performance.

In vivo dosimetry in external beam photon radiotherapy: Requirements and future directions for research, development, and clinical practice

External beam radiotherapy with photon beams is a highly accurate treatment modality, but requires extensive quality assurance programs to confirm that radiation therapy will be or was administered appropriately. In vivo dosimetry (IVD) is an essential element of modern radiation therapy because it provides the ability to catch treatment delivery errors, assist in treatment adaptation, and record the actual dose delivered to the patient. However, for various reasons, its clinical implementation has been slow and limited. The purpose of this report is to stimulate the wider use of IVD for external beam radiotherapy, and in particular of systems using electronic portal imaging devices (EPIDs). After documenting the current IVD methods, this report provides detailed software, hardware and system requirements for in vivo EPID dosimetry systems in order to help in bridging the current vendor-user gap. The report also outlines directions for further development and research. In vivo EPID dosimetry vendors, in collaboration with users across multiple institutions, are requested to improve the understanding and reduce the uncertainties of the system and to help in the determination of optimal action limits for error detection. Finally, the report recommends that automation of all aspects of IVD is needed to help facilitate clinical adoption, including automation of image acquisition, analysis, result interpretation, and reporting/documentation. With the guidance of this report, it is hoped that widespread clinical use of IVD will be significantly accelerated.

Analyses of integrated EPID images for on-treatment quality assurance to account for interfractional variations in volumetric modulated arc therapy

Purpose

To investigate the effects of interfractional variation, such as anatomical changes and setup errors, on dose delivery during treatment for prostate cancer (PC) and head and neck cancer (HNC) by courses of volumetric modulated arc therapy (VMAT) aided by on‐treatment electronic portal imaging device (EPID) images.

Methods

Seven patients with PC and 20 patients with HNC who had received VMAT participated in this study. After obtaining photon fluence at the position of the EPID for each treatment arc from on‐treatment integrated EPID images, we calculated the differences between the fluence for the first fraction and each subsequent fraction for each arc. The passing rates were investigated based on a tolerance level of 3% of the maximum fluence during the treatment courses and the correlations between the passing rates and anatomical changes.

Results

In PC, the median and lowest passing rates were 99.8% and 95.2%, respectively. No correlations between passing rates and interfractional variation were found. In HNC, the median passing rate of all fractions was 93.0%, and the lowest passing rate was 79.6% during the 35th fraction. Spearman’s correlation coefficients between the passing rates and changes in weight or neck volume were − 0.77 and − 0.74, respectively.

Conclusions

Analyses of the on‐treatment EPID images facilitates estimates of the interfractional anatomical variation in HNC patients during VMAT and thus improves assessments of the need for re‐planning or adaptive strategies and the timing thereof.

The effect of the choice of patient model on the performance of in vivo 3D EPID dosimetry to detect variations in patient position and anatomy

PURPOSE

In vivo EPID dosimetry is meant to trigger on relevant differences between delivered and planned dose distributions and should therefore be sensitive to changes in patient position and patient anatomy. Three-dimensional (3D) EPID back-projection algorithms can use either the planning computed tomography (CT) or the daily patient anatomy as patient model for dose reconstruction. The purpose of this study is to quantify the effect of the choice of patient model on the performance of in vivo 3D EPID dosimetry to detect patient-related variations.

METHODS

Variations in patient position and patient anatomy were simulated by transforming the reference planning CT images (pCT) into synthetic daily CT images (dCT) representing a variation of a given magnitude in patient position or in patient anatomy. For each variation, synthetic in vivo EPID data were also generated to simulate the reconstruction of in vivo EPID dose distributions. Both the planning CT images and the synthetic daily CT images could be used as patient model in the reconstructions yielding e D pCT and e D dCT EPID reconstructed dose distributions respectively. The accuracy of e D pCT and e D dCT reconstructions was evaluated against absolute dose measurements made in different phantom setups, and against dose distributions calculated by the treatment planning system (TPS). The comparison was performed by γ-analysis (3% local dose/2 mm). The difference in sensitivity between e D pCT and e D dCT reconstructions to detect variations in patient position and in patient anatomy was investigated using receiver operating characteristic analysis and the number of triggered alerts for 100 volumetric modulated arc therapy plans and 12 variations.

RESULTS

e D dCT showed good agreement with both absolute point dose measurements (<0.5%) and TPS data (γ-mean = 0.52 ± 0.11). The agreement degraded with e D pCT , with the magnitude of the deviation varying with each specific case. e D dCT readily detected combined 3 mm translation setup errors in all directions (AUC = 1.0) and combined 3° rotation setup errors around all axes (AUC = 0.86) whereas e D pCT showed good detectability only for 12 mm translations (AUC = 0.85) and 9° rotations (AUC = 0.80). Conversely, e D pCT manifested a higher sensitivity to patient anatomical changes resulting in AUC values of 0.92/0.95 for a 6 mm patient contour expansion/contraction compared to 0.70/0.64 with e D dCT . Using |ΔPTV_D50 | > 3% as clinical tolerance level, the percentage of alerts for 6 mm changes in patient contour were 85%/27% with e D pCT / e D dCT .

CONCLUSIONS

With planning CT images as patient model, EPID dose reconstructions underestimate the dosimetric effects caused by errors in patient positioning and overestimate the dosimetric effects caused by changes in patient anatomy. The use of the daily patient position and anatomy as patient model for in vivo 3D EPID transit dosimetry improves the ability of the system to detect uncorrected errors in patient position and it reduces the likelihood of false positives due to patient anatomical changes.

A method to verify sections of arc during intrafraction portal dosimetry for prostate VMAT

This study investigates the use of a running sum of images during segment-resolved intrafraction portal dosimetry for volumetric modulated arc therapy (VMAT), so as to alert the operator to an error before it becomes irremediable. At the time of treatment planning, predicted portal images were created for each segment of the VMAT arc, and at the time of delivery, intrafraction monitoring software polled the portal imager to read new images as they became available. The predicted and measured images were compared and displayed on a segment basis. In particular, a running sum of images from ten segments (a 'section') was investigated, with mean absolute difference between predicted and measured images being quantified. Images for 13 prostate patients were used to identify appropriate tolerance values for this statistic. Errors in monitor units of 2%-10%, field size of 2-10 mm, field position of 2-10 mm and path length of 10-50 mm were deliberately introduced into the treatment plans and delivered to a water-equivalent phantom and the sensitivity of the method to these errors was investigated. Gross errors were also considered for one case. The patient images show considerable variability from segment to segment, but when using a section of the arc the variability is reduced, so that the maximum value of mean absolute difference between predicted and measured images is reduced to below 12%, after excluding the first 10% of segments. This tolerance level is also found to be applicable for delivery of the plans to a water-equivalent phantom. Using this as a tolerance level for the error plans, a 10% increase in monitor units is detected, 4 mm increase or shift in multileaf collimator settings can be detected, and an air gap of dimensions 40 mm  ×  50 mm is detected. Gross errors can also be detected instantly after the first 10% of segments. The running difference between predicted and measured images over ten segments is able to identify errors at specific regions of the arc, as well as in the overall treatment.

Electronic Portal Imaging Device-Based Three-Dimensional Volumetric Dosimetry for Intensity-modulated Radiotherapy Pretreatment Quality Assurance

Aim:

This study aimed at evaluating the efficacy of treatment planning system (TPS)-based heterogeneity correction for two- and three-dimensional (2D and 3D) electronic portal imaging device (EPID)-based pretreatment dose verification. An experiment was conducted on the EPID back-projection technique and intensity-modulated radiotherapy (IMRT).

Materials and Methods:

Treatment plans were delivered in EPID without a patient to obtain the fluence pattern (F_EPID). A heterogeneity correction plane (F_het) for an open beam of 30 cm × 30 cm was extracted from the TPS. The heterogeneity-corrected measured fluence is developed by matrix element multiplication (F_Resultant = F_EPID × F_het). Further planes were summed to develop a 3D dose distribution and exported to the TPS. Dose verifications for 2D and 3D were carried out with the corresponding TPS values using 2D gamma analysis (ɣ) and dose volume histogram (DVH) comparison, respectively. Totally, 33 patients (17 head–neck and 16 thorax cases) were evaluated in this study.

Results:

The head–neck and thorax plans show a 3-mm-distance to agreement (DTA) 3% DD gamma passing of 96.3% ± 2.0% and 95.4% ± 1.8% points, respectively, between F_TPS and F_Resultant. The comparison of the uncorrected measured fluence (F_EPID) with F_TPS reveals a gamma passing of 82.2% ± 7.3% and 80.4% ± 8.6% for head–neck and thorax cases, respectively. A total of 87 out of the 102 head–neck and thorax beams exhibit a planner gamma passing of 97.6% ± 2.1%. In the 3D-DVH comparison of thorax and head–neck cases, D5% for planning target volume were −0.5% ± 2.2% and −2.1% ± 3.5%, respectively; D95% varies as 1.0% ± 2.7% and 1.4% ± 1.1% between TPS calculated and heterogeneity-corrected-EPID-based dose reconstruction.

Conclusion:

The novel TPS-based heterogeneity correction can improve the 2D and 3D EPID-based back projection technique. Structures with large heterogeneities can also be handled using the proposed technique.

Evaluation of interfraction setup variations for postmastectomy radiation therapy using EPID-based in vivo dosimetry

Postmastectomy radiation therapy is technically difficult and can be considered one of the most complex techniques concerning patient setup reproducibility. Slight patient setup variations — particularly when high‐conformal treatment techniques are used — can adversely affect the accuracy of the delivered dose and the patient outcome. This research aims to investigate the inter‐fraction setup variations occurring in two different scenarios of clinical practice: at the reference and at the current patient setups, when an image‐guided system is used or not used, respectively. The results were used with the secondary aim of assessing the robustness of the patient setup procedure in use. Forty eight patients treated with volumetric modulated arc and intensity modulated therapies were included in this study. EPID‐based in vivo dosimetry (IVD) was performed at the reference setup concomitantly with the weekly cone beam computed tomography acquisition and during the daily current setup. Three indices were analyzed: the ratio R between the reconstructed and planned isocenter doses, γ% and the mean value of γ from a transit dosimetry based on a two‐dimensional γ‐analysis of the electronic portal images using 5% and 5 mm as dose difference and distance to agreement gamma criteria; they were considered in tolerance if R was within 5%, γ% > 90% and γmean < 0.4. One thousand and sixteen EPID‐based IVD were analyzed and 6.3% resulted out of the tolerance level. Setup errors represented the main cause of this off tolerance with an occurrence rate of 72.2%. The percentage of results out of tolerance obtained at the current setup was three times greater (9.5% vs 3.1%) than the one obtained at the reference setup, indicating weaknesses in the setup procedure. This study highlights an EPID‐based IVD system's utility in the radiotherapy routine as part of the patient’s treatment quality controls and to optimize (or confirm) the performed setup procedures’ accuracy.

In-vivo EPID dosimetry for IMRT and VMAT based on through-air predicted portal dose algorithm

We have adapted the methodology of Berry et al. (2012) for Intensity Modulated Radiotherapy (IMRT) and Volumetric Modulated Arc Therapy (VMAT) treatments at a fixed source to imager distance (SID) based on the manufacturer's through-air portal dose image prediction algorithm. In order to fix the SID a correction factor was introduced to account for the change in air gap between patient and imager. Commissioning data, collected with multiple field sizes, solid water thicknesses and air gaps, were acquired at 150 cm SID on the Varian aS1200 EPID. The method was verified using six IMRT and seven VMAT plans on up to three different phantoms. The method's sensitivity and accuracy were investigated by introducing errors. A global 3%/3 mm gamma was used to assess the differences between the predicted and measured portal dose images. The effect of a varying air gap on EPID signal was found to be significant - varying by up to 30% with field size, phantom thickness, and air gap. All IMRT plans passed the 3%/3 mm gamma criteria by more than 95% on the three phantoms. 23 of 24 arcs from the VMAT plans passed the 3%/3 mm gamma criteria by more than 95%. This method was found to be sensitive to a range of potential errors. The presented approach provides fast and accurate in-vivo EPID dosimetry for IMRT and VMAT treatments and can potentially replace many pre-treatment verifications.